title: Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era.
abstract: BACKGROUND
  We have assessed the survival rate of patients with non-small cell lung cancer and synchronous hematogenous solitary metastasis identified with complete staging workup, including total body [18F]fluorodeoxyglucose positron emission tomography scan, and treated with a multidisciplinary approach.
  
  
  METHODS
  We examined the database of all patients who underwent surgery for primary non-small cell lung cancer in our institute. The criteria required for inclusion in this analysis were diagnosis of non-small cell lung cancer with synchronous hematogenous solitary metastasis by staging workup with total body computed tomography scan and brain magnetic resonance if indicated, total body positron emission tomography scan, radical surgery for the primary tumors, local treatment of the solitary metastasis, and systemic chemotherapy administration.
  
  
  RESULTS
  We analyzed the data from 1,509 patients treated from January 2000 to December 2005: 10 patients (0.7%) satisfied the selection criteria. The median overall survival was 26 months, and the median time to progression was 20 months; 6 patients were alive at the time of analysis, with a median follow-up of 30 months. Four patients were tumor progression-free after 9, 18, 23, and 32 months from the start of their treatment.
  
  
  CONCLUSIONS
  The presentation of non-small cell lung cancer with a synchronous hematogenous solitary metastasis identified by [18F]fluorodeoxyglucose positron emission tomography containing complete staging workup is extremely rare. This subset of patients can achieve long-term survival after a multidisciplinary treatment approach.
authors.affiliation: New Drugs Development Unit, Department of Medicine, European Institute of Oncology, Milan, Italy. tommaso.de-pas@ieo.it
authors.forename: Tommaso M
authors.initials: TM
authors.lastname: De Pas
authors.forename: Filippo
authors.initials: F
authors.lastname: de Braud
authors.forename: Gianpiero
authors.initials: G
authors.lastname: Catalano
authors.forename: Carlo
authors.initials: C
authors.lastname: Putzu
authors.forename: Giulia
authors.initials: G
authors.lastname: Veronesi
authors.forename: Francesco
authors.initials: F
authors.lastname: Leo
authors.forename: Piero G
authors.initials: PG
authors.lastname: Solli
authors.forename: Daniela
authors.initials: D
authors.lastname: Brambilla
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganelli
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Spaggiari
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D012189:Retrospective Studies
chemical_list: D019788:Fluorodeoxyglucose F18